Surveillance for Adverse Events Following Influenza Immunization
NCT ID: NCT01318876
Last Updated: 2012-08-21
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
7645 participants
OBSERVATIONAL
2010-10-31
2011-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Passive surveillance is collecting notifications of adverse events (AE) on the whole population but the sensitivity of this system is not high and its timeliness is not necessarily optimal. Last year, with the new pandemic Influenza vaccine the investigators piloted a web-based active surveillance of a large number of health care workers (HCW) vaccinated with the new adjuvanted monovalent pH1N1 influenza vaccine (Arepanrix® GSK, Canada). Because healthcare workers (HCW) constituted a well-defined group with general good health and received the Influenza vaccine in priority, this group of people was well suited for monitoring the safety of the influenza vaccine. For this study, 6242 HCW were recruited in three different sites (5183 were from Quebec). A total of 468 events (local reactions, fever, systemic reactions, gastrointestinal and respiratory problems) were reported by 430 HCW. 80% of the HCW recruited completed at least one of the three surveys and 52% responded to all questionnaires. During this surveillance, the investigators didn't have unexpected findings but this active surveillance of adverse events among healthcare workers would have been effective enough to rapidly detect adverse events occurring at a rate ≥ 1 per 200 vaccinees. For this year the investigators want to expand the surveillance to more sites and more participants to be able to detect AE occurring at rates ≥ 1 per 500 vaccinees, and to increase the response rate to all three surveys in participants.
The main objective of this project is to estimate in HCW vaccinated against influenza the frequency of adverse events of sufficient severity to cause work absenteeism or medical consultation.
This year the network will include 5 Canadian hospitals (Quebec City, Vancouver, Toronto, Halifax, + another one ) with a total enrollment of \>10 000 HCW. This should allow us to detect AE occurring at a rate of ≥ 1 per 500 vaccinees.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
BC Children's and Women's Hospital, Vancouver.
No interventions assigned to this group
University of British Columbia, Vancouver.
No interventions assigned to this group
Health care workers in Halifax
No interventions assigned to this group
Health care workers from CHUQ hospitals
No interventions assigned to this group
Health care workers from Toronto
No interventions assigned to this group
Centre hospitalier et universitaire de Sherbrooke
No interventions assigned to this group
The Ottawa General Hospital, Ottawa
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* To have been immunized with the influenza vaccine 2010
* To have an email address
* To be 18 years old and older
* To have sign the consent form
Exclusion Criteria
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
GlaxoSmithKline
INDUSTRY
Institut National en Santé Publique du Québec
OTHER
Laval University
OTHER
CHU de Quebec-Universite Laval
OTHER
Mount Sinai Hospital, Canada
OTHER
IWK Health Centre
OTHER
Centre de recherche du Centre hospitalier universitaire de Sherbrooke
OTHER
The Ottawa Hospital
OTHER
University of British Columbia
OTHER
PHAC/CIHR Influenza Research Network
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Gaston De Serres
Epidemiologist at the National Institute of Public Health of Quebec and professor of epidemiology at the University Laval
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Canadian Center for Vaccinology, Halifax
Halifax, Nova Scotia, Canada
The Ottawa General Hospital,
Ottawa, Ontario, Canada
Mount Sinai Hospital, Toronto
Toronto, Ontario, Canada
BC Children's and Women's Hospital, Vancouver
Vancouver, British Columbia, Canada
University of British Columbia,
Vancouver, British Columbia, Canada
Centre Hospitalier Universitaire de Québec
Québec, Quebec, Canada
Centre Hospitalier et Universitaire de Sherbrooke
Sherbrooke, Quebec, Canada
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
De Serres G, Gariepy MC, Coleman B, Rouleau I, McNeil S, Benoit M, McGeer A, Ambrose A, Needham J, Bergeron C, Grenier C, Sleigh K, Kallos A, Ouakki M, Ouhoummane N, Stiver G, Valiquette L, McCarthy A, Bettinger J; PHAC-CIHR influenza Research Network (PCIRN). Short and long-term safety of the 2009 AS03-adjuvanted pandemic vaccine. PLoS One. 2012;7(7):e38563. doi: 10.1371/journal.pone.0038563. Epub 2012 Jul 3.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
pcirn-surveillancehcw-1011
Identifier Type: -
Identifier Source: org_study_id